• Publications
  • Influence
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
TLDR
Caplacizumab induced a faster resolution of the acute TTP episode than did placebo, and the platelet-protective effect of caplacIZumab was maintained during the treatment period.
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
TLDR
AlX-0061 represents a minimized bispecific biotherapeutic of 26 kDa, nearly six times smaller than monoclonal antibodies, and is supportive of clinical development in RA.
Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.
TLDR
Preclinical data demonstrate that ALX-0081 combines a high efficacy with an improved safety profile compared with currently marketed antithrombotics.
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells
TLDR
The nanobody platform may be highly effective at generating extremely potent and selective G protein-coupled receptor modulators in response to conventional monoclonal antibodies.
Shielding of the A1 Domain by the D′D3 Domains of von Willebrand Factor Modulates Its Interaction with Platelet Glycoprotein Ib-IX-V*
TLDR
The results support a model of domain translocation in VWF that allows interaction with GPIbα and the suggested shielding interaction of the A1 domain by the D′D3 region then becomes disrupted by VWF immobilization.
Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs.
TLDR
The inhibition of the GPIb-VWF axis in guinea pigs prevents cerebral artery thrombosis and induces early reperfusion without provoking intracerebral bleeding thus reducing brain infarct area.
Platelet antigens and their function
TLDR
Based on the detailed study of the antigens that are recog-nized by alloantibodies, for example, polymorphisms on anumber of platelet receptors have been identified as Human Platelet Antigen (HPA)-systems and classed as HPA-systems.
Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.
TLDR
It is demonstrated that ALX-0681 can successfully treat and prevent the most important hallmarks of acquired TTP without evidence of a severe bleeding risk, and offers an attractive new therapeutic option for acquired T TP in the clinical setting.
Identification of Residues within Human Glycoprotein VI Involved in the Binding to Collagen
TLDR
Observations suggest that ligand-binding sites are distinct, exhibiting specific features but at the same time also sharing some common residues participating in the recognition of these ligands.
Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.
TLDR
In contrast to the commonly used GPIIb/IIIa antagonists, the blockade of GPIb a with Mab Ib-23 effectively reduces the prothrombotic MP generation and thrombin formation at shear rates typically found in arterial stenoses.
...
...